09/28/2015
Co-Chair Daniel Einhorn, MD, FACP, FACE, Clinical Professor of Medicine, University of California; Medical Director, Scripps Whittier Diabetes Institute; Associate Editor, Journal of Diabetes; President, Diabetes and Endocrine Associates; talks with fellow Co-Chair Edward Shahady, MD, FAAFP, ABCL about the early results of SGLT2 inhibitors and the cardiovascular benefits and cardiac outcomes.
